Eli Lilly and Boehringer partnered to co-develop and co-commercialize a portfolio of diabetes candidates, including two products from each company

Eli Lilly and Co.

U.S. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Boehringer Ingelheim GmbH

Germany / Private Biopharma

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced